Tags

Type your tag names separated by a space and hit enter

Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Clin Liver Dis 2017; 21(4):739-753CL

Abstract

Nonalcoholic fatty liver disease (NAFLD) is recognized as a global health problem and as a common cause of chronic liver disease. Nonalcoholic steatohepatitis (NASH) carries an increased risk for development of advanced liver disease. Lifestyle modifications with diet and exercise have been the initial management recommendation. However, these changes are difficult to achieve and sustain overtime. There are pharmacologic agents being considered for treatment of NASH. Some target insulin resistance and others focus on oxidative stress, inflammation, apoptosis, and fibrosis. There is a great deal of efforts to develop therapeutic regimens for patients with NASH and NASH with significant fibrosis.

Authors+Show Affiliations

Betty and Guy Beatty Center for Integrated Research, Inova Health System, Inova Fairfax Hospital, Claude Moore Health Education and Research Building, 3rd Floor, 3300 Gallows Road, Falls Church, VA 22042, USA.Betty and Guy Beatty Center for Integrated Research, Inova Health System, Inova Fairfax Hospital, Claude Moore Health Education and Research Building, 3rd Floor, 3300 Gallows Road, Falls Church, VA 22042, USA.Betty and Guy Beatty Center for Integrated Research, Inova Health System, Inova Fairfax Hospital, Claude Moore Health Education and Research Building, 3rd Floor, 3300 Gallows Road, Falls Church, VA 22042, USA; Department of Medicine, Center for Liver Disease, Inova Fairfax Hospital, Claude Moore Health Education and Research Building, 3rd Floor, 3300 Gallows Road, Falls Church, VA 22042, USA. Electronic address: Zobair.Younossi@inova.org.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28987260

Citation

Golabi, Pegah, et al. "Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis." Clinics in Liver Disease, vol. 21, no. 4, 2017, pp. 739-753.
Golabi P, Bush H, Younossi ZM. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Liver Dis. 2017;21(4):739-753.
Golabi, P., Bush, H., & Younossi, Z. M. (2017). Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clinics in Liver Disease, 21(4), pp. 739-753. doi:10.1016/j.cld.2017.06.010.
Golabi P, Bush H, Younossi ZM. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Liver Dis. 2017;21(4):739-753. PubMed PMID: 28987260.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. AU - Golabi,Pegah, AU - Bush,Haley, AU - Younossi,Zobair M, Y1 - 2017/07/29/ PY - 2017/10/9/entrez PY - 2017/10/11/pubmed PY - 2018/6/6/medline KW - Clinical trials KW - NAFLD KW - NASH KW - Nonantifibrotics KW - Treatment SP - 739 EP - 753 JF - Clinics in liver disease JO - Clin Liver Dis VL - 21 IS - 4 N2 - Nonalcoholic fatty liver disease (NAFLD) is recognized as a global health problem and as a common cause of chronic liver disease. Nonalcoholic steatohepatitis (NASH) carries an increased risk for development of advanced liver disease. Lifestyle modifications with diet and exercise have been the initial management recommendation. However, these changes are difficult to achieve and sustain overtime. There are pharmacologic agents being considered for treatment of NASH. Some target insulin resistance and others focus on oxidative stress, inflammation, apoptosis, and fibrosis. There is a great deal of efforts to develop therapeutic regimens for patients with NASH and NASH with significant fibrosis. SN - 1557-8224 UR - https://www.unboundmedicine.com/medline/citation/28987260/Treatment_Strategies_for_Nonalcoholic_Fatty_Liver_Disease_and_Nonalcoholic_Steatohepatitis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1089-3261(17)30058-2 DB - PRIME DP - Unbound Medicine ER -